Rhythm Technologies has seen its consensus analyst price target rise modestly to $205 per share. This move reflects recent positive performance and an optimistic outlook. The increase comes as ...

Those taking the drug, which contains a substance banned in many other countries, are experiencing severe side effects.

Budgets feel tight, deals look huge, and the clock keeps ticking. Black Friday brings both relief and risk for every household. On Friday 28 November ...